Time New York: Tue 20 Aug 21:30 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Ecolab’s Chemstar Buyout to Boost Food & Beverage Business

Zacks

Ecolab Inc. ECL recently acquired Chemstar Corporation with a view to expand its Food & Beverage unit. The deal value has been kept under wraps.

For investors’ notice, privately-held Chemstar is a supplier of food safety, cleaning and sanitizing solutions focused on the grocery and food retail markets. Notably, Chemstar’s flagship product, Sterilox Fresh, has been driving the company’s top line and is much in demand in both the United States and Canada.

Per management at Ecolab, Sterilox Fresh produces treatment solutions to help the food retail industry meet increasing consumer demand for fresh food and floral products.

Into Ecolab’s Food & Beverage Unit


At the Food & Beverage unit, Ecolab serves the Beverage processing, Cheese processing, Meat, Poultry & Seafood, Biofuels & Ethanol, Dairy Processing, Brewery & Winery and Food Processing markets.

Notably, Ecolab’s Food & Beverage offerings fall under the Global Institutional revenue segment.

In the recently-reported second quarter of 2019, Ecolab’s Global Institutional revenues rose 1.2% year over year to $1.31 billion.
In a bid to boost its Food & Beverage unit, Ecolab has acquired Holchem Group of late. (Read More: Ecolab to Boost Food Safety Standards With Holchem Buyout)

Market Prospects

Per statista, the global Food & Beverage market had a net worth of $93,582 million in 2018. Markedly, the market value is expected to see a CAGR of 10.3% to reach a value of $152,677 million by 2023.

Hence, the latest move has been a well-timed one for Ecolab.

Other key players in this space are IBM IBM, Unilever UN and Procter & Gamble PG. While IBM’s use of blockchain technology in food safety currently faces robust demand, Unilever and Procter & Gamble’s food safety measures also deserve a mention.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.